The Joint Committee on Vaccination and Immunisation (JCVI) has approved the use of a lower dose of the Pfizer vaccine for clinically vulnerable children aged between five and 11.
Around 300,000 children deemed to be at clinical risk from the virus or living with someone who is immunosuppressed should be offered two 10mg doses of the vaccine - a third of the amount given to adults - eight weeks apart.
The JCVI’s decision came after the UK’s medicine watchdog, the Medicines and Healthcare products Regulatory Agency (MHRA), approved the use of the Pfizer vaccine for them.
Register Now to Continue Reading
Thank you for visiting Children & Young People Now and making use of our archive of more than 60,000 expert features, topics hubs, case studies and policy updates. Why not register today and enjoy the following great benefits:
What's Included
-
Free access to 4 subscriber-only articles per month
-
Email newsletter providing advice and guidance across the sector
Already have an account? Sign in here
